Nymox Pharmaceutical Corporation (NYMXF)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Peers in Healthcare
Nymox Pharmaceutical Corporation has no peer companies in this window.
Recent press releases
Nymox Pharmaceutical Corporation has not issued a press release in this window.
SEC filings
All filings →Nymox Pharmaceutical Corporation has not filed an SEC document in this window.
Insider trades
All insider trades →Nymox Pharmaceutical Corporation has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Nymox Pharmaceutical Corporation
All people →No officers or directors have been indexed for Nymox Pharmaceutical Corporation.